Bill > SB190

This bill establishes the Pharmaceutical Transparency Review Board, an independent state board tasked with reviewing high-cost prescription drug products and developing recommendations to address affordability challenges for residents, government agencies, health plans, providers, and other stakeholders. The seven-member board, appointed by various state legislative leaders, will consist of individuals with expertise in health care economics or clinical medicine, with strict conflict of interest provisions to ensure independence. The board will be required to collect detailed information from drug manufacturers about drug development costs, pricing, marketing expenses, profits, patient assistance programs, and financial incentives, focusing on prescription drugs that meet specific cost thresholds or are deemed to create affordability burdens. By January 2028, the board must submit a comprehensive report analyzing prescription drug costs, supply chain dynamics, price transparency, and patient out-of-pocket expenses, as well as annual reports on drug price trends. The board will be funded through assessments on pharmaceutical manufacturers and will have the authority to impose daily fines of $20,000 for non-compliance. The bill aims to increase transparency in pharmaceutical pricing and develop strategies to make prescription drugs more affordable in Pennsylvania, with the board's work to begin 60 days after the act's enactment.

Business and Industry

https://www.legis.state.pa.us/cfdocs/billinfo/bill_history.cfm?syear=2025&sind=0&body=S&type=B&bn=190